1.14
전일 마감가:
$1.12
열려 있는:
$1.14
하루 거래량:
1.51M
Relative Volume:
0.76
시가총액:
$191.44M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.6909
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
-2.56%
1개월 성능:
-5.79%
6개월 성능:
-30.91%
1년 성능:
-65.03%
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.14 | 191.44M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2023-03-27 | 재개 | Wells Fargo | Equal Weight |
2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2022-12-15 | 개시 | Goldman | Sell |
2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
2022-10-10 | 개시 | Canaccord Genuity | Buy |
2022-08-18 | 재개 | Wells Fargo | Overweight |
2022-07-28 | 개시 | Needham | Hold |
2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | 개시 | Robert W. Baird | Neutral |
2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
2021-12-07 | 개시 | Cowen | Outperform |
2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
2021-04-26 | 재개 | Jefferies | Buy |
2021-02-26 | 개시 | BofA Securities | Buy |
2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-01-27 | 재개 | H.C. Wainwright | Neutral |
2020-05-13 | 개시 | H.C. Wainwright | Buy |
2020-03-04 | 개시 | Barclays | Overweight |
2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | 재확인 | Mizuho | Buy |
2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
2019-11-12 | 개시 | SunTrust | Buy |
2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
2019-10-01 | 개시 | Stifel | Buy |
2019-08-09 | 개시 | BTIG Research | Buy |
2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
2019-07-12 | 개시 | Oppenheimer | Outperform |
2019-06-13 | 개시 | Mizuho | Buy |
2019-06-07 | 개시 | ROTH Capital | Neutral |
2019-05-31 | 개시 | Guggenheim | Buy |
2019-05-24 | 재개 | Citigroup | Buy |
2019-03-28 | 개시 | SVB Leerink | Outperform |
2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
2018-11-05 | 개시 | Jefferies | Buy |
2018-08-01 | 개시 | Citigroup | Buy |
2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st
Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com
TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World
Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus
Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance
Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada
Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times
Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq
Fate’s FT819 shows promising results in lupus patients - Investing.com
Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan
Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Two Sigma Investments LP Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Jane Street Group LLC Has $51,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Millennium Management LLC Increases Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Ameriprise Financial Inc. Sells 72,581 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Public Employees Retirement System of Ohio Sells 46,100 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc (NASDAQ:FATE) Price Forecast For The Next 12 Months Is Set At 3. - Marketing Sentinel
ProShare Advisors LLC Has $56,000 Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down - Nasdaq
Fate Therapeutics appoints new board member - Investing.com
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewswire
Fate Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Fate Therapeutics to present lupus treatment data at EULAR 2025 By Investing.com - Investing.com South Africa
Fate Therapeutics to present lupus treatment data at EULAR 2025 - Investing.com Australia
Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases - Insider Monkey
Prime Mining: Expanding a High-Grade Gold and Silver Resource in Mexico - The Globe and Mail
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - The Manila Times
Viridian Metals: Targeting Critical Copper Discoveries in Newfoundland - The Globe and Mail
Fate Therapeutics Announces Phase 1 Data Presentation of - GlobeNewswire
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewswire Inc.
Northern Trust Corp Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress By Investing.com - Investing.com Canada
Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress - Investing.com
BNP Paribas Financial Markets Raises Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Reports Q1 2025 Financial Results - TipRanks
Price T Rowe Associates Inc. MD Cuts Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
StockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to Hold - Defense World
Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World
Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World
What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN
Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fate Therapeutics Inc 주식 (FATE) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Bressi Jerome Charles | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,980 |
9,269 |
270,203 |
TAHL CINDY | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,654 |
8,764 |
336,707 |
Valamehr Bahram | President and CEO |
Jan 10 '25 |
Sale |
1.54 |
8,705 |
13,406 |
349,364 |
자본화:
|
볼륨(24시간):